| Characteristic | No. (%) of patients | Cardiac monitoring | Cardiotoxicity | |||||
|---|---|---|---|---|---|---|---|---|
| No. (%) of patients with sufficient cardiac monitoring n = 2859 | No. (%) of patients without sufficient cardiac monitoring n = 918 | p value* | No. (%) of patients with cardiotoxicity n = 640 | No. (%) of patients without cardiotoxicity n = 3137 | p value* | |||
| Age, yr | 0.3 | 0.02 | ||||||
| < 45 | 843 | 623 (73.9) | 220 (26.1) | 123 (14.6) | 720 (85.4) | |||
| 45-64 | 2312 | 1757 (76.0) | 555 (24.0) | 392 (17.0) | 1920 (83.0) | |||
| > 64 | 622 | 479 (77.0) | 143 (23.0) | 125 (20.1) | 497 (79.9) | |||
| ≥ 2 comorbidities | 172 | 123 (71.5) | 49 (28.5) | 0.2 | 42 (24.4) | 130 (75.6) | < 0.01 | |
| Previous HF | 46 | 31 (67.4) | 15 (32.6) | 0.2 | 18 (39.1) | 28 (60.9) | < 0.01 | |
| Hypertension | 1144 | 883 (77.2) | 261 (22.8) | 0.2 | 198 (17.3) | 946 (82.7) | 0.7 | |
| Previous MI | 13 | 9 (69.2) | 4 (30.8) | 0.6 | 4 (30.8) | 9 (69.2) | 0.2 | |
| Diabetes | 356 | 247 (69.4) | 109 (30.6) | < 0.01 | 71 (19.9) | 285 (80.1) | 0.1 | |
| Income quintile | 0.3 | 0.3 | ||||||
| Q1 | 630 | 461 (73.2) | 169 (26.8) | 120 (19.0) | 510 (80.9) | |||
| Q2 | 716 | 550 (76.8) | 166 (23.2) | 127 (17.7) | 589 (82.3) | |||
| Q3 | 753 | 556 (73.8) | 197 (26.2) | 117 (15.5) | 636 (84.5) | |||
| Q4 | 810 | 621 (76.7) | 189 (23.3) | 142 (17.5) | 668 (82.5) | |||
| Q5 | 857 | 660 (77.0) | 197 (23.0) | 134 (15.6) | 723 (84.4) | |||
| Rural | 472 | 396 (83.9) | 76 (16.1) | < 0.01 | 90 (19.1) | 382 (80.9) | 0.2 | |
| Calendar period | 0.01 | < 0.01 | ||||||
| 2003-2007 | 2393 | 1780 (74.4) | 613 (25.5) | 476 (19.9) | 1917 (80.1) | |||
| 2008-2009 | 1384 | 1079 (78.0) | 305 (22.0) | 164 (11.8) | 1220 (88.1) | |||
Note: HF = heart failure, MI = myocardial infarction, Q = quintile.
*χ2 test.